Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evogene Ltd.EVGN · Entity 8065 | Director | September 04, 2026 | September 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evogene Ltd.
Report date September 04, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2036-09-04 | Direct | 2,500 |
Reported balance
After 2026-09-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-04 · Grant · Acquired 2,500 · Balance 2,500 F1: The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date. F2: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 2,500 Options under the Issuer's 2021 Share Incentive Plan. F3: The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.60 · Expires 2028-12-23 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 1,000 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.89 · Expires 2030-02-01 | Direct | 250 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 250 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.68 · Expires 2031-02-01 | Direct | 250 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 250 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.80 · Expires 2031-08-10 | Direct | 1,800 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 1,800 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.20 · Expires 2032-09-15 | Direct | 1,800 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 1,800 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2033-05-11 | Direct | 1,800 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 1,800 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.60 · Expires 2034-06-13 | Direct | 1,800 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 1,800 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2035-08-18 | Direct | 2,500 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 2,500 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date.
F2: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 2,500 Options under the Issuer's 2021 Share Incentive Plan.
F3: The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date.
F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 30, 2026 08:07 UTC | Evogene Ltd. EVGN · Entity 8065 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001178913-26-004660 · ownership.xml · derivative · entry 1 Percy Adrian John · CIK 0001980816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Ordinary Shares · 2,500 shares Expires 2036-09-04 F1 · derivative.exercise_price: The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date. F2 · kind: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 2,500 Options under the Issuer's 2021 Share Incentive Plan. F3 · derivative.exercise_date: The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.